Navigation Links
Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
Date:6/12/2012

LEXINGTON, Mass., June 12, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs, announced today that Michael D. Rivard has joined the company as Vice President, Corporate Development.

Mr. Rivard has over 20 years of experience in the biotechnology industry and has held senior management positions in corporate development at ArQule, Inc., Synta Pharmaceuticals Corp., Galenea Corp., and VaxDesign Corporation.  Mr. Rivard also served as Associate Counsel (Intellectual Property) at the University of Massachusetts and as an Associate Attorney at the law firm of Palmer & Dodge (now Edwards Wildman Palmer LLP).  Mr. Rivard earned a Juris Doctor degree from the UCLA School of Law and a BA degree in biochemistry from Bowdoin College.

"I am thrilled to join this exciting company," said Mr. Rivard.  "The AVX Oral Antibody™ technology makes the gastrointestinal (GI) tract accessible to potent and safe antibody therapy.  Potential applications for our antibodies include inflammatory bowel disease (IBD), oral mucositis, GI acute radiation syndrome, celiac disease, diabetes, and any other disease which involves an antigen, soluble protein, or receptor in the GI tract or oral cavity.  The breadth of the platform offers many opportunities to work with collaborators in the pharmaceutical industry as we develop our lead product for IBD."

Barbara S. Fox, CEO of Avaxia, added, "Mike brings to Avaxia a unique mix of knowledge and experience in corporate development, intellectual property, and corporate law, as well as a scientific background.  We are confident that Mike will lead us successfully in achieving our goals of partnering our AVX-470 oral anti-TNF antibody and finding collaborators who share our vision of developing oral antibodies for other exciting targets in the GI tract."

About Avaxia Biologics, Inc.: Avaxia Biologics is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics and have nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies™ make disease targets in the GI tract readily accessible to antibody therapeutics.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
2. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... ... Bleep LLC, maker of the DreamPort mask-less CPAP solution, announced today that ... , “In my line of work, a good night of sleep is critical to ... a Bleeping no brainer for me,” said Jensen. “From the moment I started using ...
(Date:8/27/2020)... ... ... The GHT Companies , a leading developer and distributor of nutraceutical ... with a press conference at its manufacturing facility in Vista. Here are ... an overall donation result exceeding $30,000 to Feeding San Diego, Who: Jim Rex, ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... Eurofins BioPharma Services, Laboratory Testing division, expands its technology footprint with the ... Flow Cytometry platforms available. With industry-leading biomarker solutions, complemented with traditional ligand-binding ...
Breaking Medicine Technology:
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... Feeding ... care for children with Pediatric Feeding Disorder (PFD), is pleased to announce that the ... a stand-alone diagnostic code (R code) in the next edition of the U.S. ...
(Date:9/1/2020)... ... 01, 2020 , ... Dr. Kiran Gill is a Board ... the face, breast, and body. In 2018, she founded Aesthetics in Plastic Surgery ... aesthetic practice in Southwest Florida. Dr. Gill and her team offer surgical and ...
(Date:8/31/2020)... ... August 31, 2020 , ... The ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... 10th Anniversary of Blood Cancer Awareness Month (BCAM) and its international Light ...
(Date:8/31/2020)... Miss. (PRWEB) , ... August 31, 2020 , ... ... (GCPP) recently donated 1,400 N95 face masks to medical first responders across the ... continued to make donations of personal protective equipment (PPE) medical centers , ...
(Date:8/31/2020)... ... August 31, 2020 , ... Genesis Chiropractic Software ... today the launch of its integrated, HIPAA compliant, telehealth solution, available to US-based ... in under 90 seconds. , According to the U.S. Department of Health ...
Breaking Medicine News(10 mins):